Literature DB >> 16027729

cFos is critical for MCF-7 breast cancer cell growth.

Chunhua Lu1, Qiang Shen, Elizabeth DuPré, Heetae Kim, Susan Hilsenbeck, Powel H Brown.   

Abstract

The activating protein-1 (AP-1) transcription factor is a converging point of multiple signal transduction pathways in many cells. We have previously demonstrated that overexpressing Tam67, a dominant-negative (DN) form of cJun, blocks AP-1 activity and inhibits breast cancer cell growth. We hypothesized that Tam67 forms dimers with other AP-1 proteins to suppress the growth of breast cancer cells. In the present study, we used immunoprecipitation-Western blotting to demonstrate that Tam67 binds all Jun and Fos proteins in breast cancer cells. In addition, we used two variants of the Tam67 mutant to investigate whether Jun or Fos protein was required for breast cancer cell growth. We created a Tam/Fos mutant in which the cJun dimerization domain was replaced by the cFos dimerization domain, and a Tam/Squelcher mutant in which the cJun dimerization domain was deleted. We then isolated MCF-7 cell lines that stably expressed these cJun-DN mutants under the control of an inducible promoter. Using AP-1-dependent reporter assays, we observed that Tam67 and Tam/Fos mutants inhibited AP-1 transcriptional activity, while the Tam/Squelcher mutant did not. We then determined whether Tam/Fos or Tam/Squelcher inhibited breast cell growth as well as Tam67. We found that while Tam67 repressed cell growth, neither Tam/Fos nor Tam/Squelcher mutant affected cell growth. These results indicate that Tam67 likely inactivates Fos family member proteins to suppress breast cancer cell growth. Finally, we performed antisense experiments to knock down the expression of individual family members (cJun or cFos). Our results demonstrated that antisense cFos inhibited breast cancer cell proliferation and colony formation, while antisense cJun did not. These results suggest that Tam67 suppresses breast cancer cell growth by interacting with Fos family members, specifically with cFos, to produce an inactive AP-1 complex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027729     DOI: 10.1038/sj.onc.1208905

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Geraniol modulates cell proliferation, apoptosis, inflammation, and angiogenesis during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis.

Authors:  Veerasamy Vinothkumar; Shanmugam Manoharan; Ganapathy Sindhu; Madhavan Ramados Nirmal; Venkatesan Vetrichelvi
Journal:  Mol Cell Biochem       Date:  2012-06-23       Impact factor: 3.396

Review 2.  Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.

Authors:  Mian M K Shahzad; Yong-Hyun Shin; Koji Matsuo; Chunhua Lu; Masato Nishimura; De-Yo Shen; Yu Kang; Wei Hu; Edna M Mora; Cristian Rodriguez-Aguayo; Arvinder Kapur; Justin Bottsford-Miller; Gabriel Lopez-Berestein; Aleksandar Rajkovic; Anil K Sood
Journal:  Cancer Lett       Date:  2012-07-07       Impact factor: 8.679

3.  Knockdown of c-Fos suppresses the growth of human colon carcinoma cells in athymic mice.

Authors:  Manoj K Pandey; Guangming Liu; Timothy K Cooper; Kathleen M Mulder
Journal:  Int J Cancer       Date:  2011-04-08       Impact factor: 7.396

4.  TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.

Authors:  Jin Liu; Bryan Welm; Ken M Boucher; Mark T W Ebbert; Philip S Bernard
Journal:  Am J Pathol       Date:  2011-12-02       Impact factor: 4.307

5.  γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells.

Authors:  Lihua Song; Aiying Du; Ying Xiong; Jing Jiang; Yao Zhang; Zhaofeng Tian; Hongli Yan
Journal:  Tumour Biol       Date:  2016-09-19

6.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

7.  Dual targeting of EphA2 and FAK in ovarian carcinoma.

Authors:  Mian M K Shahzad; Chunhua Lu; Jeong-Won Lee; Rebecca L Stone; Rahul Mitra; Lingegowda S Mangala; Yiling Lu; Keith A Baggerly; Christopher G Danes; Alpa M Nick; Jyotsnabaran Halder; Hye-Sun Kim; Pablo Vivas-Mejia; Charles N Landen; Gabriel Lopez-Berestein; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2009-06-24       Impact factor: 4.742

8.  EphA2 overexpression promotes ovarian cancer growth.

Authors:  Chunhua Lu; Mian M K Shahzad; Hua Wang; Charles N Landen; Seung W Kim; Julie Allen; Alpa M Nick; Nicholas Jennings; Michael S Kinch; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2008-04-19       Impact factor: 4.742

9.  A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.

Authors:  Dana Inbar-Rozensal; Asher Castiel; Leonid Visochek; David Castel; Françoise Dantzer; Shai Izraeli; Malka Cohen-Armon
Journal:  Breast Cancer Res       Date:  2009-11-09       Impact factor: 6.466

10.  Molecular profiles of pre- and postoperative breast cancer tumours reveal differentially expressed genes.

Authors:  Margit L H Riis; Torben Lüders; Elke K Markert; Vilde D Haakensen; Anne-Jorun Nesbakken; Vessela N Kristensen; Ida R K Bukholm
Journal:  ISRN Oncol       Date:  2012-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.